%0 Journal Article
%T Non©\small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
%A Jin Wang
%A Jing Huang
%A Yachao Zhai
%A Yiyin Wang
%J Archive of "Thoracic Cancer".
%D 2018
%R 10.1111/1759-7714.12637
%X The most common EGFR mutations in non©\small cell lung cancer are exon 19 deletions and exon 21 point mutations, which are both sensitive to EGFR©\tyrosine kinase inhibitors. However, rare EGFR mutations do exist and how these mutations respond to tyrosine kinase inhibitors is not well understood. A Chinese woman diagnosed with stage IV lung adenocarcinoma harbored a rare EGFR L747P (2239©\2240 TT£¿>£¿CC) mutation, and treatment with gefitinib and osimertinib failed to achieve the desired effect. Herein, possible correlations between gene analysis and the outcomes of subsequent treatment are discussed
%K EGFR L747P
%K lung cancer
%K osimertinib
%K pembrolizumab
%K TKI
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983145/